Resource

Learn about liquid biopsy and the dPCR approach

World Health Organization statistics show that nearly 10 million people worldwide died from cancer in 2020, with 20 million new cases diagnosed in that year. Liquid biopsies are used to identify and track genetic mutations in cancer samples—enabling researchers to detect cancer early—measure therapeutic response, quantify residual tumor burden, and monitor emerging resistance to therapies.

Liquid biopsies utilize cell free DNA (cfDNA) derived from both normal and cancerous cells. The component of cfDNA that is released from cancer cells is commonly referred to as circulating tumor DNA, or ctDNA.

Join Atocha Romero, Head of the Liquid Biopsy Laboratory at Hospital Universitario Puerta Hierro, Majadahonda, Spain in this on-demand webinar, to learn about the analysis of ctDNA by dPCR, which has several applications:

ctDNA genotyping can be used for non invasive biomarker testing, which is especially relevant in testing lung cancer samples
ctDNA levels correlate well with tumor bulk
ctDNA levels are of prognostic significance, as ctDNA levels have been shown to correlate well with survival outcomes

A short preview of the full webinar:

Please fill out the short form below to view this recorded webinar.

(*Indicates a mandatory field)

First Name*

Last Name*

Institution*

Email*

City*

Country/Region*

I am a current digital PCR user*

Yes

I am looking to incorporate or upgrade to digital PCR in the lab

Within the next 0–6 months

Within 12 months

Evaluating technology only

I would like a sales representative to contact me for a quote or demo about the QuantStudio Absolute Q Digital PCR System*

Yes